Cumberland Pharmaceuticals Inc. has amended its existing revolving credit agreement with Pinnacle Bank, increasing the principal available for borrowing to $15 million, with the option to request an additional $10 million, maintaining a total aggregate principal of up to $25 million. The amendment extends the maturity date of the facility to October 1, 2027, and continues to require Cumberland to meet a minimum fixed charge coverage ratio and borrowing base requirements on a quarterly basis. The interest rate on borrowings is set at Benchmark Term SOFR plus 2.75%, and the credit line is secured by substantially all of the company's assets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-25-000023), on November 24, 2025, and is solely responsible for the information contained therein.